<DOC>
	<DOCNO>NCT01155063</DOCNO>
	<brief_summary>Evaluating safety , tolerability efficacy Aromasin® use routine clinical practice , evaluate adherence prescribe Aromasin® treatment understand reason early discontinuation .</brief_summary>
	<brief_title>Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients</brief_title>
	<detailed_description>This study terminate 01-Aug-2011 due low potential enroll plan number patient sufficient number patient complete statistical analysis . This study terminate safety efficacy concern .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal female . Patients surgical treatment histological confirm breast cancer nonmetastatic time initial diagnosis . Patients diseasefree 2 3 year adjuvant tamoxifen treatment . Patients whose tumour estrogen receptor positive ( ER+ ) . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Patients Aromasin® treatment contraindicate ( see SPC ) . Presence metastasis contra lateral tumour . Other adjuvant endocrine therapy . Another concomitant antineoplastic treatment . Participation clinical trial investigational drug 30 day prior enrolment study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Exemestane</keyword>
	<keyword>Adjuvant Treatment In Postmenopausal Women</keyword>
	<keyword>Estrogen Receptor Positive Early Breast Cancer</keyword>
	<keyword>Tamoxifen</keyword>
</DOC>